Comprehensive mutational analysis of five major clinical ß-lactamases to elucidate evolvability and family-level trends

对五种主要临床β-内酰胺酶进行全面突变分析，以阐明进化性和家族水平趋势

• 批准号: 486000
• 负责人: Lee Dongkyu
• 金额: $ 1.27万
• 依托单位: University of British Columbia
• 依托单位国家: 加拿大
• 项目类别: Studentship Programs
• 财政年份: 2022
• 资助国家: 加拿大
• 起止时间: 2022-12-01 至 2023-12-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=486000&lang=en
• 关键词: Antimicrobial Resistance; Deep Mutational Scanning; Gram-Negative Pathogen; Host Adaptability; Inhibitor Escape; Metallo-ß-Lactamase; Mutagenesis; Serine-ß-Lactamase; ß-Lactam Antibiotic; ß-Lactamase Inhibitor

Antimicrobial resistance (AMR) continues to be a growing health concern—by 2050, AMR infections are projected to cost 396,000 Canadian lives and $388 billion to the Canadian economy. Among pathogenic bacteria, ?-lactamases (BLs) are a commonly observed re

抗菌素耐药性（AMR）仍然是一个日益严重的健康问题，到2050年，AMR感染预计将导致396，000加拿大人死亡，加拿大经济损失3880亿美元。在致病菌中，内酰胺酶（BL）是一种常见的反应，